in a randomized , double-blind trial , 253 patients with congestive heart failure ( new york heart association class iv ) received either enalapril ( n = 127 ) or placebo ( n = 126 ) in addition to their existing therapeutic regimens ( consisting of digitalis , diuretics , and vasodilators other than angiotensin-converting enzyme inhibitors ) .
C0018802
congestive heart failure
C0014025
enalapril